Farmers & Merchants Trust Co of Chambersburg PA lowered its position in Abbott Laboratories (NYSE:ABT) by 23.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,368 shares of the healthcare product maker’s stock after selling 2,000 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA’s holdings in Abbott Laboratories were worth $340,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ABT. Sanders Morris Harris LLC raised its position in Abbott Laboratories by 0.3% in the 2nd quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock worth $242,000 after purchasing an additional 16 shares during the last quarter. St. Louis Trust Co raised its position in Abbott Laboratories by 0.4% in the 2nd quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock worth $238,000 after purchasing an additional 20 shares during the last quarter. Lakeview Capital Partners LLC raised its position in Abbott Laboratories by 0.6% in the 2nd quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock worth $277,000 after purchasing an additional 33 shares during the last quarter. Johanson Financial Advisors Inc. raised its position in Abbott Laboratories by 0.5% in the 2nd quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock worth $343,000 after purchasing an additional 37 shares during the last quarter. Finally, Country Club Trust Company n.a. raised its position in Abbott Laboratories by 0.5% in the 2nd quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock worth $356,000 after purchasing an additional 38 shares during the last quarter. Institutional investors own 71.12% of the company’s stock.

In other news, insider Jaime Contreras sold 52,700 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total value of $2,738,819.00. Following the completion of the transaction, the insider now owns 58,739 shares of the company’s stock, valued at approximately $3,052,665.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the transaction, the insider now directly owns 10,256 shares of the company’s stock, valued at approximately $572,900.16. The disclosure for this sale can be found here. Insiders sold a total of 616,332 shares of company stock valued at $33,579,226 in the last three months. 0.76% of the stock is owned by company insiders.

Several research analysts recently weighed in on ABT shares. BMO Capital Markets restated a “hold” rating and issued a $53.00 price objective on shares of Abbott Laboratories in a research report on Friday, September 1st. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Friday, September 22nd. Cowen restated a “buy” rating on shares of Abbott Laboratories in a research report on Sunday, September 24th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $57.00 to $64.00 and gave the stock an “outperform” rating in a research report on Thursday, September 28th. Finally, Barclays lifted their target price on shares of Abbott Laboratories from $57.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $57.56.

Shares of Abbott Laboratories (NYSE:ABT) opened at $56.80 on Wednesday. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a fifty-two week low of $37.90 and a fifty-two week high of $56.94. The company has a market cap of $98,169.90, a price-to-earnings ratio of 23.40, a price-to-earnings-growth ratio of 2.11 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the previous year, the business earned $0.59 EPS. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. equities analysts forecast that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a $0.28 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date is Thursday, January 11th. This represents a $1.12 annualized dividend and a dividend yield of 1.97%. Abbott Laboratories’s payout ratio is 83.47%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/abbott-laboratories-abt-shares-sold-by-farmers-merchants-trust-co-of-chambersburg-pa/1774079.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.